ibrutinib bendamustine/rituximab in patients with previously treated cll/sll
Published 8 years ago • 1.9K plays • Length 8:51Download video MP4
Download video MP3
Similar videos
-
8:51
ibrutinib bendamustine/rituximab in patients with previously treated cll/sll
-
6:44
ibrutinib combined with bendamustine plus rituximab in previously treated cll and sll
-
6:12
ibrutinib comb. w/ bendamustine & rituximab in previously treated cll/sll
-
5:29
helios trial: ibrutinib combined with br for previously treated cll/sll
-
2:04
updated long-term follow-up of sequoia: zanubrutinib vs bendamustine-rituximab in untreated cll/sll
-
7:47
ibrutinib combined with bendamustine and rituximab in cll/sll
-
6:12
ibrutinib comb. with bendamustine & rituximab in previously treated cll/sll
-
3:35
trial of ibrutinib with bendamustine and rituximab in cll: results and study design
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
1:44
ibrutinib and fcr in cll irrespective of ighv mutation status
-
1:31
acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or r/r mcl
-
4:39
jennifer woyach: ibrutinib outperforms chemoimmunotherapy in cll
-
1:23
captivate: fixed-duration ibrutinib plus venetoclax in patients with cll/sll
-
2:02
helios: phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
1:16
dr. jones on long-term outcomes with ibrutinib in cll
-
2:07
sequoia: zanubrutinib vs br in treatment-naïve cll/sll
-
4:12
combining a targeted drug with chemotherapy offers longer life to patients with b-cell cancers
-
6:13
jeff p. sharman, md: ublituximab plus ibrutinib improves response rate in high-risk cll